Welcome to the McLaughlin Lab for Clinical and Translational Metabolic Research at Stanford University
Metabolic health lives at the intersection of physiology, genetics and lifestyle. We are interested in the role of adipocyte physiology in the development of insulin resistance, diabetes, cardiovascular disease and obesity, as well as how diet and medications relate to these effects. We are leveraging our clinical and basic science knowledge to design thoughtful clinical studies that will ultimately improve human metabolic health.
Currently, our interests center around the use of continuous glucose monitoring and multi-omics methods to define metabolic phenotypes and precision diets for individuals with pre-diabetes and Type 2 Diabetes. We are also interested in the role of incretin hormones in glucose metabolism and Post-Bariatric and Post-Total Gastrectomy Hypoglycemia.
Currently Enrolling Participants
We are currently enrolling participants! Please contact Nicole Turk at nturk@stanford.edu if you are interested.
Longitudinal Multi-omic Profiles to Reveal Mechanisms for Obesity-Mediated Insulin Resistance ("Metabolic Challenge") : https://clinicaltrials.gov/study/NCT05165706?term=NCT05165706&rank=1
Currently Enrolling Participants
The role of the gut in regulating glucose metabolism has become increasingly clear. Bariatric surgery alters gut hormone secretion, leading to the resolution of diabetes and, in some cases, severe hypoglycemia. Our lab is home to cutting-edge research on the physiological basis and treatment of post-bariatric hypoglycemia.
We are currently enrolling participants. Please contact Nicole Turk at nturk@stanford.edu for more information!
Role of Nutrient Transit and Incretin Hormones in Hyperinsulinemic Hypoglycemia: https://clinicaltrials.gov/study/NCT04615546?term=NCT04615546&rank=1
This study is open for enrollment! We are looking for overweight non-diabetic participants who are willing to lose weight. Participants will be randomized into the Mounjaro group or the Diet group. The diet group will be on a strict calorie deficit diet to match the weight loss of the Mounjaro group for at least 6 weeks. Please contact Nicole Turk at nturk@stanford.edu if you are interested or follow the QR code below:
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity: https://clinicaltrials.gov/study/NCT05912621?term=%09NCT05912621&rank=1
Improving Glycemic Control Using a Virtual Weight Control Program and Continuous Glucose Monitoring (VITAL-CGM): https://classic.clinicaltrials.gov/ct2/show/NCT05935514?term=05935514&draw=2&rank=1
We are looking for individuals with a diagnosis of Type 2 Diabetes to participate in our weight loss study in collaboration with Weight Watchers. Participants will get access to the Weight Watchers app, continuous glucose monitoring, and virtual group workshops. You may be compensated up to $225 upon completion of this 1 year study. If you're interested, please follow the QR code below or this link to fill out a quick survey.
Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions: https://classic.clinicaltrials.gov/ct2/show/NCT05721729?term=vogenx&draw=2&rank=1
In collaboration with Vogenx Inc., we are looking at the effects of Mizagliflozin in individuals with post-bariatric hypoglycemia for this phase IIb trial. We are currently enrolling participants! Please contact Nicole Turk at nturk@stanford.edu if you are interested.
Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2 infection and inflammation in human adipose tissue: https://classic.clinicaltrials.gov/ct2/show/NCT05833217?term=05833217&draw=2&rank=1
We are currently enrolling participants! Please contact Nicole Turk at nturk@stanford.edu if you are interested.